IriSys clinical trial material manufacturing contract upped to $6m

23-Apr-2017 - Last updated on 24-Apr-2017 at 14:20 GMT

IriSys is responsible for formulation studies, process optimization, clinical dosage form manufacture, release testing, quality control, and quality assurance. (Image: iStock/Sergei_Aleshin)

IriSys LLC has been awarded an increase to its five-year prime vendor contract – an agreement now worth up to $6m.

The San Diego, California-based contract pharmaceutical product development and manufacturing services (CDMO) company was awarded the contract by the National Cancer Institute (NCI)'s Developmental Therapeutics Program (DTP) of the Division of Cancer Treatment and Diagnosis (DCTD).

The original contract was awarded in 2015 and will continue through 2020.

“This is the second five-year prime vendor contract that IriSys has received; the first was in place from 2010 until 2015, when the second contract was awarded,” Louis Scotti, vice president, business development at IriSys told Outsourcing-Pharma.com.

Per the contract, IriSys will continue to manufacture oral, topical, and injectable dosage forms for NCI-sponsored and/or investigator-initiated clinical trials.

“IriSys will be creating and improving (where necessary) formulations of drugs that the NCI has selected for clinical trials,” said Scotti.

IriSys has the capacity for the envisioned work, Scotti explained, as the company recently doubled its capacity after moving into a new facility in 2015, at which time the company also increased its scientific staff by 60%.

“However, IriSys is willing and prepared to invest in additional capacity should new contracts from commercial biopharma companies and the NIH/NCI require such capacity expansion,” he added.

All work will be carried at the company’s 24,500 sq. ft. facility in San Diego.